PHARMALIXHE: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
What changed
PHARMALIXHE
NACE 47.730, Retail sale of pharmaceutical products
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
€24,699
2024 · €33,648-€8,949
Equity
€293,509
2024 · €270,310+€23,199
Cash
€111,697
2024 · €104,220+€7,477
Balance sheet total
€476,967
2024 · €457,189+€19,777
Largest movements
Assets
- Stocks and contracts +€9,775
up €9,775 (+7.7%), from €126,256 to €136,031
- Cash +€7,477
up €7,477 (+7.2%), from €104,220 to €111,697
mainly Net result for the year (+€24,699) and Depreciation (+€2,841)
Equity and liabilities
- Reserves +€23,000
up €23,000 (+14.3%), from €161,300 to €184,300
Income statement
- Staff costs +€16,577
up €16,577 (+12.0%), from €137,726 to €154,303
- Gross operating margin +€3,448
up €3,448 (+1.8%), from €192,911 to €196,359
- Taxes -€3,050
down €3,050 (-23.4%), from €13,041 to €9,991
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Result 2024
€33,648
Gross operating margin
+€3,448
Staff costs
-€16,577
Depreciation
+€263
Other operating charges
+€166
Other operating items
+€259
Financial income
-€502
Financial charges
+€944
Taxes
+€3,050
Result 2025
€24,699
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
From operations
+€13,458
Investment
-€4,482
Financing
-€1,500
Cash 2024
€104,220
From operations (derived)
+€13,458
Net result for the year
+€24,699
Depreciation
+€2,841
Stocks and contracts
-€9,775
Receivables within one year
-€1,498
Deferred charges and accrued income
+€613
Trade debts
-€1,345
Tax, wage and social debts
+€872
Other debts
-€1,920
Accrued charges and deferred income
-€1,029
Investment (derived)
-€4,482
Investment in fixed assets (net)
-€4,482
Financing
-€1,500
Contributions, distributions and other
-€1,500
Cash 2025
€111,697
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €457,189 | €476,967 | +€19,777 | +4.3% |
| Fixed assets | 21/28 | €6,169 | €7,810 | +€1,641 | +26.6% |
| Tangible fixed assets | 22/27 | €6,169 | €7,810 | +€1,641 | +26.6% |
| Furniture and vehicles | 24 | €3,426 | €5,417 | +€1,991 | +58.1% |
| Other tangible fixed assets | 26 | €2,743 | €2,393 | -€350 | -12.8% |
| Current assets | 29/58 | €451,020 | €469,157 | +€18,137 | +4.0% |
| Stocks and contracts in progress | 3 | €126,256 | €136,031 | +€9,775 | +7.7% |
| Stocks | 30/36 | €126,256 | €136,031 | +€9,775 | +7.7% |
| Amounts receivable within one year | 40/41 | €69,142 | €70,640 | +€1,498 | +2.2% |
| Trade receivables | 40 | €59,173 | €64,387 | +€5,214 | +8.8% |
| Other amounts receivable | 41 | €9,968 | €6,252 | -€3,716 | -37.3% |
| Current investments | 50/53 | €149,163 | €149,163 | = | 0.0% |
| Cash at bank and in hand | 54/58 | €104,220 | €111,697 | +€7,477 | +7.2% |
| Deferred charges and accrued income | 490/1 | €2,239 | €1,626 | -€613 | -27.4% |
| Total equity and liabilities | 10/49 | €457,189 | €476,967 | +€19,777 | +4.3% |
| Equity | 10/15 | €270,310 | €293,509 | +€23,199 | +8.6% |
| Contributions | 10/11 | €108,600 | €108,600 | = | 0.0% |
| Reserves | 13 | €161,300 | €184,300 | +€23,000 | +14.3% |
| Distributable reserves | 133 | €161,300 | €184,300 | +€23,000 | +14.3% |
| Profit (loss) carried forward | 14 | €410 | €609 | +€199 | +48.5% |
| Amounts payable | 17/49 | €186,879 | €183,458 | -€3,422 | -1.8% |
| Amounts payable within one year | 42/48 | €178,745 | €176,353 | -€2,393 | -1.3% |
| Trade debts | 44 | €44,925 | €43,581 | -€1,345 | -3.0% |
| Suppliers | 440/4 | €44,925 | €43,581 | -€1,345 | -3.0% |
| Taxes, remuneration and social security | 45 | €28,599 | €29,471 | +€872 | +3.1% |
| Taxes | 450/3 | €6,875 | €7,212 | +€337 | +4.9% |
| Remuneration and social security | 454/9 | €21,724 | €22,259 | +€535 | +2.5% |
| Other amounts payable | 47/48 | €105,221 | €103,301 | -€1,920 | -1.8% |
| Accrued charges and deferred income | 492/3 | €8,134 | €7,105 | -€1,029 | -12.7% |
| Remuneration, social security and pensions | 62 | €137,726 | €154,303 | +€16,577 | +12.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €3,104 | €2,841 | -€263 | -8.5% |
| Other operating charges | 640/8 | €371 | €205 | -€166 | -44.8% |
| Non-recurring operating charges | 66A | €259 | - | -€259 | |
| Gross operating margin | 9900 | €192,911 | €196,359 | +€3,448 | +1.8% |
| Operating profit (loss) | 9901 | €51,452 | €39,010 | -€12,441 | -24.2% |
| Financial income | 75/76B | €4,230 | €3,728 | -€502 | -11.9% |
| Recurring financial income | 75 | €4,230 | €3,728 | -€502 | -11.9% |
| Financial charges | 65/66B | €8,993 | €8,048 | -€944 | -10.5% |
| Recurring financial charges | 65 | €8,993 | €8,048 | -€944 | -10.5% |
| Profit (loss) for the period before taxes | 9903 | €46,689 | €34,690 | -€11,999 | -25.7% |
| Income taxes | 67/77 | €13,041 | €9,991 | -€3,050 | -23.4% |
| Profit (loss) for the period | 9904 | €33,648 | €24,699 | -€8,949 | -26.6% |
| Profit (loss) for the period to be appropriated | 9905 | €33,648 | €24,699 | -€8,949 | -26.6% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.